Clinical Trial Update: Lenvatinib Combined Pembrolizumab in Advanced Hepatobiliary Tumors [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating lenvatinib combined with pembrolizumab in advanced hepatobiliary tumors has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholangiocarcinoma
• Liver Neoplasm

Drugs mentioned

• Lenvatinib (lenvatinib)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Peking Union Medical College Hospital | Conditions: Liver Neoplasm Malignant Primary, Cholangiocarcinoma | Phase 2 | Status: COMPLETED